Instagram Outage Disrupts Thousands of U.S. Users 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
HEIDELBERG, Germany, Nov. 09, 2016 -- Affimed N.V. (Nasdaq:AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Jefferies 2016 London Healthcare Conference on Wednesday, November 16, 2016 at 4:00 p.m. (GMT) in London.
A live webcast of the conference presentation can be accessed through the “Events” section on the “Media” page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq:AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact: Caroline Stewart, Head IR Phone: +1 347394 6793 E-Mail: [email protected] or [email protected] Media Contact: Anca Alexandru, Head of Communications, EU IR Phone: +49 6221 64793341 E-Mail: [email protected]
